

Financial news for PVCT dated on 2020-03-24: Stocks That Hit 52-Week Highs On Tuesday

Financial news for PVCT dated on 2016-08-24: Provectus Biopharmaceuticals Proposes "Best Efforts" Public Offering

Financial news for PVCT dated on 2016-08-24: Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Preferred Stock and Warrants

Financial news for PVCT dated on 2016-08-23: Provectus Biopharma Announces Patent For Rose Bengal Analogs

Financial news for PVCT dated on 2016-07-18: Provectus Biopharma Gets Patent For Halogenated Xanthenes

Financial news for PVCT dated on 2016-07-14: Provectus Biopharma Announces Australian Subsidiary Formed

Financial news for PVCT dated on 2016-07-13: Provectus Biopharmaceuticals Announces PV-10 Data Discussed at 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Financial news for PVCT dated on 2016-07-12: Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at ESMO 2016 Congress

Financial news for PVCT dated on 2016-06-13: Provectus Biopharmaceuticals Enters Stipulation Of Settlement In Shareholder Derivative Action

Financial news for PVCT dated on 2016-06-07: Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology, Shows Disease Control Achieved In 63% Of Patients On 11.7 Month Follow Up

Financial news for PVCT dated on 2016-05-19: Provectus Biopharma Reports Abstract Available on PV-10 Plus Radiotherapy in Melanoma

Financial news for PVCT dated on 2016-04-22: Provectus Will Report Data on PV-10 in Combo Therapy, T-Cell Mediated Immunity at AACR Meeting

Financial news for PVCT dated on 2016-04-22: UPDATE: Provectus Says Presentation Showed Treatment with IL PV-10 and Anti-PD-1 Antibody Results in a Delay in Tumor Growth and Enhanced T Cell Activation in the M05 Tumor Model

Financial news for PVCT dated on 2016-04-22: Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at AACR Annual Meeting 2016

Financial news for PVCT dated on 2016-03-30: Provectus Biopharma Reports Q4 Cash, Cash Equivalents \$14.179M vs \$17.39M in Same Qtr. Last Year

Financial news for PVCT dated on 2016-03-16: Provectus Biopharmaceuticals Amends Protocol for Phase 3 Study of PV-10 in Treatment of Locally Advanced Cutaneous Melanoma

Financial news for PVCT dated on 2016-03-16: Provectus Biopharmaceuticals Files Non-Timely 10K

Financial news for PVCT dated on 2016-03-16: Provectus Announces Results of Internal Investigation of Audit Committee

Financial news for PVCT dated on 2016-02-29: Provectus Biopharmaceuticals Says Initiates Phase 1 Study of PV-10 in Neuroendocrine Tumors Metastatic to Liver

Financial news for PVCT dated on 2016-01-20: Top Performing Industries For January 20, 2016

Financial news for PVCT dated on 2016-01-12: Provectus Biopharma Announces First Patents for PV-10

Financial news for PVCT dated on 2015-09-29: Provectus Biopharmaceuticals Reports Publication of Review Paper on PV-10 Tumor Ablation and Immune Stimulation

Financial news for PVCT dated on 2015-08-18: Provectus Biopharmaceuticals Given US Patent Protecting Use of PV-10 as Part of Combination Therapy for Cancer

Financial news for PVCT dated on 2015-07-22: Provectus Biopharmaceuticals to Hold Q2 Business Update Conference Call on Thursday, August 6, 2015

Financial news for PVCT dated on 2015-07-06: Provectus Biopharmaceuticals' Phase 1 PV-10 Data on Liver Cancer Presented at 6th Asia-Pacific Primary Liver Cancer Expert Meeting

Financial news for PVCT dated on 2015-07-02: Provectus Biopharma Reports Signing of Letter of Intent with Boehringer Ingelheim (China) to Collab in Bringing PV-10 to Market in China

Financial news for PVCT dated on 2015-06-24: Provectus Biopharmaceuticals Announces Abstract Available on PV-10 for Chemoablation of Liver Cancers at ESMO 17th World Congress on Gastrointestinal Cancer

Financial news for PVCT dated on 2015-06-19: Provectus Biopharma Prices Offering of 17.5M Shares at \$0.75/Share for Gross Proceeds ~\$13.1M

Financial news for PVCT dated on 2015-06-18: Provectus Biopharma Announces Intention Of Public Offering, Proceeds From Offering Will Be Used For Clinical Development, Working Capital, And General Purposes

Financial news for PVCT dated on 2015-06-01: Provectus Biopharmaceuticals' Data on PV-10 as Intralesional Treatment of Melanoma Presented at 2015 American Society of Clinical Oncology Annual Meeting

Financial news for PVCT dated on 2015-05-18: Provectus Biopharmaceuticals Extends for 60 Days MoU With Sinopharm-China State Institute of Pharmaceutical Industry, Sinopharm A-Think Pharmaceutical

Financial news for PVCT dated on 2015-04-20: Pfizer and Provectus Biopharmaceuticals Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancer

Financial news for PVCT dated on 2015-04-15: Provectus Biopharmaceuticals Opens Patient Enrollment; Starts Phase 3 International FDA Comparative Clinical Trial of PV-10 for Melanoma

Financial news for PVCT dated on 2015-03-12: Provectus Biopharmaceuticals Awarded PH-10 Patent by USPTO

Financial news for PVCT dated on 2015-01-27: Stocks With Unusual Volume For Jan 27: HQY, PCCC, NVMI, MDWD, PVCT

Financial news for PVCT dated on 2014-12-23: Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Makers of Psoriasis

Financial news for PVCT dated on 2014-12-22: Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed

Financial news for PVCT dated on 2014-11-06: Provectus Biopharmaceuticals Submits PV-10 Phase 3 Melanoma Protocol to FDA

Financial news for PVCT dated on 2014-11-06: Provectus Shares Halted News Pending

Financial news for PVCT dated on 2014-10-14: INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticals

Financial news for PVCT dated on 2014-09-29: Provectus Biopharmaceuticals Presents Data Showing Ablative, Bystander Effects of PV-10 at ESMO 2014

Financial news for PVCT dated on 2014-08-18: Provectus Biopharmaceuticals Enters into Non-Binding MOU with Sinopharm-China Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical to License and Commercialize PV-10, in China -8-K

Financial news for PVCT dated on 2014-07-08: Provectus Biopharma Says it's In Position to Embark on Phase 3 Study of Intralesional PV-10 for Metastatic Melanoma

Financial news for PVCT dated on 2014-06-24: Provectus Biopharmaceuticals Shares Spike Lower; May be Attributed to Seeking Alpha Post

Financial news for PVCT dated on 2014-06-12: Mid-Day Market Movers For Thursday, June 12, 2014

Financial news for PVCT dated on 2014-06-12: Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma

Financial news for PVCT dated on 2014-05-27: Provectus Biopharmaceuticals Opening Delayed; News Appears to be that NYSE is Reviewing Listing of the Company

Financial news for PVCT dated on 2014-05-27: NYSE Reviewing Continued Listing of Common Stock of Provectus Biopharmaceuticals

Financial news for PVCT dated on 2014-05-23: UPDATE: Provectus Says Will Outline Details of Plan at ASCO on Jun. 2nd

Financial news for PVCT dated on 2014-05-23: Provectus Biopharma Issues Release Affirming 'Commitment to Bringing PV-10 to Market Notwithstanding FDA Decision on Breakthrough Therapy Designation'

Financial news for PVCT dated on 2014-05-23: Provectus Pharma Shares Halted News Pending

Financial news for PVCT dated on 2014-05-19: Market Wrap for May 19: Markets Finish Higher On M&A Monday

Financial news for PVCT dated on 2014-05-19: Mid-Afternoon Market Update: Markets Drift Higher Amid A Flurry Of Weekend M&A Activity

Financial news for PVCT dated on 2014-05-13: Provectus Biopharmaceutics to List on NYSE

Financial news for PVCT dated on 2014-04-21: Provectus' PV-10 Clinical Data on Treatment of Melanoma to Be Presented at 10th EADO Congress

Financial news for PVCT dated on 2014-03-24: Provectus Biopharmaceuticals Submits Application to FDA for Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma

Financial news for PVCT dated on 2014-01-23: Adam Feuerstein Tweet: 'Obsolescence of \$PVCT Skin Cancer Drug Means Current Speculative Run Ends Badly'

Financial news for PVCT dated on 2013-09-13: Provectus Receives Novel Synthesis Patent

Financial news for PVCT dated on 2012-01-18: Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma